SVRA vs TARA

Savara, Inc. vs Protara Therapeutics, Inc. — Valuation Comparison 2026

SVRA

Biotechnology
Savara, Inc.
Quality
4.5
out of 10
Value Trap
30
LOW
Price
$5.09
Last close
Models
7/13
Active
VS

TARA

Biotechnology
Protara Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$4.75
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType SVRA Fair ValueSVRA Upside TARA Fair ValueTARA Upside
Bayesian DCF Intrinsic $1.41 -72.2% $1.39 -70.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.40 -92.2% $0.90 -82.3%
Dynamic NAV Asset-Based $0.93 -81.7% $2.67 -43.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SVRA vs TARA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SVRA vs TARA — Which Stock Is More Undervalued?

SVRA scores higher with a 4.5/10 quality rating vs TARA's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Savara, Inc. (SVRA) and Protara Therapeutics, Inc. (TARA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SVRA currently trades at $5.09 with a QOC of 4.5/10, while TARA trades at $4.75 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).